Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 9/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037626 | 0.91 | TGM2 (0.65) | TGM2KDM4ETSHRTP53MAPT | |
| SCHEMBL6033953 | 0.88 | TGM2 (0.62) | TGM2MAPTMAPK1ALDH1A1 | |
| SCHEMBL6034920 | 0.87 | TGM2 (0.60) | TGM2MAPTALDH1A1 | |
| SCHEMBL6033961 | 0.86 | TGM2 (0.62) | TGM2KDM4ETSHRMAPTMAPK1 | |
| SCHEMBL6034313 | 0.84 | TGM2 (0.64) | TGM2MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6034346 | 0.83 | MAPK1 (0.63) | TGM2KDM4ETSHRMAPTMAPK1 | |
| SCHEMBL6037629 | 0.81 | TGM2 (0.61) | TGM2KDM4EMAPTALDH1A1 | |
| SCHEMBL6033995 | 0.80 | TGM2 (0.59) | TGM2KDM4ETP53MAPTMAPK1 | |
| SCHEMBL6034265 | 0.79 | ALDH1A1 (0.52) | TGM2KDM4ETSHRMAPTMAPK1 | |
| SCHEMBL6034363 | 0.79 | TGM2 (0.78) | TGM2TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | TGM2 1/4885KDM4E 1774/4885TSHR 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.